{"id":1092978,"date":"2020-08-03T06:30:00","date_gmt":"2020-08-03T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/"},"modified":"2025-03-07T23:37:03","modified_gmt":"2025-03-08T04:37:03","slug":"merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/","title":{"rendered":"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio"},"content":{"rendered":"<div class=\"q4default\">\n<p class=\"bwalignc\">\n  <b>Broadens Merck Animal Health\u2019s Position with Enhanced Parasite Protection in Calves and Lambs<\/b>\n<\/p>\n<p>    MADISON, N.J.&#8211;(BUSINESS WIRE)&#8211;<br \/>\nMerck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck &amp; Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the worldwide rights to VECOXAN\u00ae (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health.\n<\/p>\n<p>\nVECOXAN is efficacious, in lambs, against the prevention of coccidiosis caused by <i>Eimeria crandallis<\/i> and <i>Eimeria ovinoidalis<\/i>, and in calves, against coccidiosis caused by <i>Eimeria bovis<\/i> and <i>Eimeria zuernii.<\/i> VECOXAN is available in Europe, South Africa, South Korea and Japan.\n<\/p>\n<p>\nParasite control and protection is an essential and significant part of ruminant overall health management and outcomes. \u201cWith advanced digital and diagnostic solutions to manage the welfare of animals as critical components of our technology, we are dedicated to advancing the health and well-being of animals and the people who take care of them,\u201d said Rick DeLuca, president, Merck Animal Health. \u201cThis complementary product for youngstock will add to our existing portfolio of veterinary medicines, including parasiticides, vaccines and services, which provides a full range of complementary solutions for our customers, and underscores our commitment to <i>The<\/i><i>Science of Healthier Animals\u00ae<\/i>.\u201d\n<\/p>\n<p>\nCoccidiosis, a common cause of scours (diarrhea) in lambs and calves that is highly prevalent on cattle and sheep farms, is caused by protozoan parasites called <i>Eimeria<\/i> that multiply in the intestinal wall, transmitted from animal to animal by the fecal-oral route. Clinical signs include painful scours with or without blood, and decreased appetite and depression, which may progress to dehydration and weight loss. Coccidiosis primarily affects young animals; calves and lambs as young as three to four weeks of age may be affected.\n<\/p>\n<p>\nCoccidiosis causes significant economic loss to farmers and producers due to reduced feed conversion, reduced growth rates, reduced performance or death, and by increased susceptibility to other infections, such as intestinal disease or Bovine Respiratory Disease.\n<\/p>\n<p>\n  <b>About VECOXAN<\/b>\n<\/p>\n<p>\nVECOXAN is an anticoccidial of the benzeneacetonitrile group without antimicrobial activity and has anticoccidial activity against <i>Eimeria species<\/i>. The product can be used in calves and lambs, beef and dairy, of any weight, in any management system, without environmental restrictions. It has a zero-day meat withdrawal period.\n<\/p>\n<p>\n  <strong>About Merck Animal Health<\/strong>\n<\/p>\n<p>\nFor more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases. Merck Animal Health, a division of Merck &amp; Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to <i>The<\/i><i>Science of Healthier Animals\u00ae<\/i>, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&amp;D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck-animal-health.com%2F&amp;esheet=52259599&amp;newsitemid=20200803005143&amp;lan=en-US&amp;anchor=www.merck-animal-health.com&amp;index=1&amp;md5=664e65ca0252269166d3f1cf2683dfd1\">www.merck-animal-health.com<\/a> or connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fshowcase%2Fmerck-animal-health%2F&amp;esheet=52259599&amp;newsitemid=20200803005143&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=0dd3092a777476eee505c13da6cfcb90\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fmerckanimalhealth&amp;esheet=52259599&amp;newsitemid=20200803005143&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=5dcce7a561131fe0843439a35918690f\">Facebook<\/a>, and Twitter at @MerckAH.\n<\/p>\n<p>\n  <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n<\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2019 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52259599&amp;newsitemid=20200803005143&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=606cffa2cdd2f0909f9c521c06435f03\">www.sec.gov<\/a>).\n<\/p>\n<p>\n  <img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n  <span class=\"bwct31415\"><\/span>\n<\/p>\n<p id=\"mmgallerylink\">\n  <span id=\"mmgallerylink-phrase\">View source version on <a href=\"http:\/\/businesswire.com\">businesswire.com<\/a>: <\/span><br \/>\n  <span id=\"mmgallerylink-link\"><br \/>\n    <a href=\"https:\/\/www.businesswire.com\/news\/home\/20200803005143\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20200803005143\/en\/<\/a><br \/>\n  <\/span>\n<\/p>\n<p>\nMerck<br \/>\n<br \/>Media:<br \/>\n<br \/>Hester de Voogd<br \/>\n<br \/>+1 (201) 463-0407<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Hester.de.voogd@merck.com\">Hester.de.voogd@merck.com<\/a><\/p>\n<p>\nPam Eisele<br \/>\n<br \/>+1 (267) 305-3558<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Pamela.Eisele@merck.com\">Pamela.Eisele@merck.com<\/a><\/p>\n<p>\nMerck<br \/>\n<br \/>Investors:<br \/>\n<br \/>Michael DeCarbo<br \/>\n<br \/>+ 1 (908) 740-1807<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Michael.DeCarbo@merck.com\">Michael.DeCarbo@merck.com<\/a><\/p>\n<p>Source: Merck &amp; Co., Inc.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Broadens Merck Animal Health\u2019s Position with Enhanced Parasite Protection in Calves and Lambs Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck &amp; Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the worldwide rights to VECOXAN\u00ae (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health. VECOXAN is efficacious, in lambs, against the prevention of coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis , and in calves, against coccidiosis caused by Eimeria bovis and Eimeria zuernii. VECOXAN is available in Europe, South Africa, South Korea and Japan. Parasite control and protection is an essential and significant part of ruminant overall health management and outcomes. \u201cWith advanced digital and diagnostic solutions to manage the welfare of animals as critical components of our technology, we are<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[65,74,289],"class_list":["post-1092978","news_item","type-news_item","status-publish","hentry","tag-animal-health","tag-merck-animal-health","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Broadens Merck Animal Health\u2019s Position with Enhanced Parasite Protection in Calves and Lambs Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck &amp; Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the worldwide rights to VECOXAN\u00ae (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health. VECOXAN is efficacious, in lambs, against the prevention of coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis , and in calves, against coccidiosis caused by Eimeria bovis and Eimeria zuernii. VECOXAN is available in Europe, South Africa, South Korea and Japan. Parasite control and protection is an essential and significant part of ruminant overall health management and outcomes. \u201cWith advanced digital and diagnostic solutions to manage the welfare of animals as critical components of our technology, we are\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:37:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/\",\"name\":\"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-08-03T06:30:00+00:00\",\"dateModified\":\"2025-03-08T04:37:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio - Merck.com","og_description":"Broadens Merck Animal Health\u2019s Position with Enhanced Parasite Protection in Calves and Lambs Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck &amp; Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the worldwide rights to VECOXAN\u00ae (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health. VECOXAN is efficacious, in lambs, against the prevention of coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis , and in calves, against coccidiosis caused by Eimeria bovis and Eimeria zuernii. VECOXAN is available in Europe, South Africa, South Korea and Japan. Parasite control and protection is an essential and significant part of ruminant overall health management and outcomes. \u201cWith advanced digital and diagnostic solutions to manage the welfare of animals as critical components of our technology, we are","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:37:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/","name":"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","datePublished":"2020-08-03T06:30:00+00:00","dateModified":"2025-03-08T04:37:03+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200803005143r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN\u00ae Brand of Parasiticides for Ruminant Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"433429dc-3f2b-4606-8953-4a9bb8c31319","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_multimedia\/merck_ah_2cs_tg.jpg","size":"165611","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Animal-Health-Completes-Acquisition-of-Worldwide-Rights-to-VECOXAN-Brand-of-Parasiticides-for-Ruminant-Portfolio-2020.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/1092978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/1092978\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=1092978"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=1092978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}